ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Sept. 29, 2021)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report September 29, 2021, filed under Items 1.01 and 2.03. It states that on September 29, 2021 Arcturus Therapeutics, Inc., a wholly owned subsidiary, entered into a Lease Agreement with TPSC IX, LLC for office, research and development, engineering and laboratory space in San Diego, California, approximately 43,234 square feet. The initial term will extend ten years and eight months from the Possession Date, with a right to extend for an additional 5-year term. The company will pay an escalating base rent and a pro rata portion of property expenses and operating expenses. The signature block shows /s/ Joseph E. Payne, dated October 5, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2021

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified in its
charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number, including
area code: (858) 900-2660

(Former name or former address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 1.01. | Entry into a Material Definitive Agreement.

On September 29, 2021, Arcturus Therapeutics,
Inc. (the “ Company ”) a wholly owned subsidiary of Arcturus Therapeutics Holdings Inc. (“ Arcturus ”),
entered into a Lease Agreement (the “ Lease ”) with TPSC IX,
LLC (the “ Landlord ”) for office, research and development, engineering and laboratory space (the “ Leased
Premises ”) located at 10285 Science Center Drive, San Diego, California (the “ Property ”). The Leased Premises
will serve as an addition to Arcturus’ existing properties.

The initial term of the Lease commences upon the
Landlord’s delivery of the Leased Premises in tenant improvement readiness condition (the “ Possession Date ”).
The initial term of the Lease will extend ten years and eight months from the Possession Date, unless earlier terminated in accordance
with the Lease. The Company will have the right to extend the term of the Lease for an additional 5-year term.

Under the Lease, the Company will lease
approximately 43,234 square feet at the Property. The Company will pay an escalating base rent over the life of the Lease and its
pro rata portion of property expenses and operating expenses for the Property.

The foregoing description of the terms of the
Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, which will be filed
with the Securities and Exchange Commission (the “ Commission ”) as an exhibit to Arcturus’ Quarterly Report on
Form 10-Q for the quarter ended September 30, 2021.

Item 2.03. | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this
Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: October 5, 2021
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2021-10-05_0001193805-21-001417.htm

Size

23,185 bytes

SHA-256

081b906c4808a8a5374d167e4045209819a336fdf8e6e529abdb4776c54a865f

Our copy

SEC_ARCT_8-K_filed2021-10-05_0001193805-21-001417.htm

Original

www.sec.gov